Impact of a bronchial genomic classifier on clinical decision making in patients undergoing diagnostic evaluation for lung cancer

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Ferguson, J Scott ^a   Van Wert, Ryan ^b   Choi, Yoonha ^c   Rosenbluth, Michael J ^c   Smith, Kate Porta ^c   Huang, Jing ^c   Spira, Avrum ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Veracyte Inc   (United States)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Bronchoscopy; Clinical utility; Decision making; Gene expression; Lung cancer; Solitary pulmonary nodule

Indexed keywords

ADULT; ARTICLE; BRONCHOSCOPY; CANCER RISK; CLASSIFIER; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; PULMONOLOGIST; RISK ASSESSMENT; CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; GENETICS; GENOMICS; LUNG; LUNG NEOPLASMS; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; X-RAY COMPUTED TOMOGRAPHY;

BRONCHOSCOPY; CLINICAL DECISION-MAKING; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GENOMICS; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84977519238     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0217-1     Document Type: Article

References (27)

1. SEER Cancer Statistics Factsheets. Lung and bronchus cancer. Bethesda, MD: National Cancer Institute; 2015.
2. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
3. Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. Am J Respir Crit Care Med. 2015;191:19-33.
4. Gould MK, Tang T, Liu ILA, Lee J, Zheng C, Danforth KN, Kosco AE, Di Fiore JL, Suh DE. Recent trends in the identification of incidental pulmonary nodules. Am J Respir Crit Care Med. 2015;192:1208-14.
5. Mph DEO, Ernst A, Lei X, Kovitz KL, Benzaquen S, Diaz-mendoza J, Greenhill S, Toth J, Feller-kopman D, Baram D, Karunakara R, Jimenez CA, Filner JJ, Rafeq S, Grosu HB, Ray C, Do CRG. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions : results of the AQuIRE registry. 2015. p. 1-62.
6. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest J. 2012;142:385-93.
7. Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, Parsons E, Mitra N, Brody J, Lenburg ME, Spira A. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med. 2015;373:243-51.
8. Whitney DH, Elashoff MR, Porta-Smith K, Gower AC, Vachani A, Ferguson JS, Silvestri GA, Brody JS, Lenburg ME, Spira A. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy. BMC Med Genomics. 2015;8:18.
9. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas Y-M, Calner P, Sebastiani P, Sridhar S, Beamis J, Lamb C, Anderson T, Gerry N, Keane J, Lenburg ME, Brody JS. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13:361-6.
10. Gould MK, Ananth L, Barnett PG. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest. 2007;131:383-8.
11. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, Yasufuku K, Martel S, Laberge F, Gingras M, Atkar-Khattra S, Berg CD, Evans K, Finley R, Yee J, English J, Nasute P, Goffin J, Puksa S, Stewart L, Tsai S, Johnston MR, Manos D, Nicholas G, Goss GD, Seely JM, Amjadi K, Tremblay A, Burrowes P, MacEachern P, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369:910-9.
12. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 SUPPL):93-120.
13. Tanner NT, Aggarwal J, Gould MK, Kearney P, Diette G, Vachani A, Fang KC, Silvestri GA. Management of pulmonary nodules by community pulmonologists: a multicenter observational study. Chest. 2015;148:1405-14.
14. Vachani A, Whitney DH, Parsons EC, Lenburg M, Ferguson JS, Silvestri GA, Spira A. Clinical utility of a bronchial genomic classifier in patients with suspected lung cancer. Chest. 2016. doi: 10.1016/j.chest.2016.02.636. [Epub ahead of print].
15. Wiener RS, Gould MK, Slatore CG, Fincke BG, Schwartz LM, Woloshin S. Resource use and guideline concordance in evaluation of pulmonary nodules for cancer: too much and too little care. JAMA Intern Med. 2014;174:871-80.
16. Gould MK, Ananth L, Barnett PG. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules Chest. 2007;131:383-88.
17. Swensen SJ. The probability of malignancy in solitary pulmonary nodules. Arch Intern Med. 1997;157:849.
18. McPherson JA, Davis K, Yau M, Beineke P, Rosenberg S, Monane M, Fredi JL. The clinical utility of gene expression testing on the diagnostic evaluation of patients presenting to the cardiologist with symptoms of suspected obstructive coronary artery disease. Crit Pathw Cardiol. 2013;12:37-42.
19. Herman L, Froelich J, Kanelos D, St Amant R, Yau M, Rhees B, Monane M, McPherson J. Utility of a genomic-based, personalized medicine test in patients presenting with symptoms suggesting coronary artery disease. J Am Board Fam Med. 2014;27:258-67.
20. Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, Brawer MK. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30:1025-31.
21. Badani KK, Kemeter MJ, Febbo PG, Lawrence HJ, Denes BS, Rothney MP, Rothberg MB, Brown GA. The impact of a biopsy based 17-gene genomic prostate score on treatment recommendations in men with newly diagnosed clinically prostate cancer who are candidates for active surveillance. Urol Pract. 2015;2:181-9.
22. Vachani A, Tanner NT, Aggarwal J, Mathews C, Kearney P, Fang KC, Silvestri G, Diette GB. Factors that influence physician decision making for indeterminate pulmonary nodules. Ann Am Thorac Soc. 2014;11:1586-91.
23. Michalopoulos SN, Kella N, Payne R, Yohannes P, Singh A, Hettinger C, Yousefi K, Hornberger J, Michaelopolous S. Influence of a genomic classifier on postoperative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study. Curr Med Res Opin. 2014;30:1-10.
24. Nguyen PL, Shin H, Yousefi K, Thompson DJS, Hornberger J, Hyatt AS, Badani KK, Morgan T, Feng FY. Impact of a genomic classifier of metastatic risk on postprostatectomy treatment recommendations by radiation oncologists and urologists. Urology. 2014;In review:35-40.
25. Ost DE, Gould MK. Decision making in patients with pulmonary nodules. Am J Respir Crit Care Med. 2012;185:363-72.
26. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185:1124-31.
27. Wilson TD, Houston CE, Etling KM, Brekke N. A new look at anchoring effects: basic anchoring and its antecedents. J Exp Psychol Gen. 1996;125:387-402.